An alternative processing pathway of APP reveals two distinct cleavage modes for rhomboid protease RHBDL4

Biol Chem. 2018 Nov 27;399(12):1399-1408. doi: 10.1515/hsz-2018-0259.

Abstract

Since the first genetic description of a rhomboid in Drosophila melanogaster, tremendous efforts have been geared towards elucidating the proteolytic mechanism of this particular class of intramembrane proteases. In particular, mammalian rhomboid proteases sparked our interest and we aimed to investigate the human homologue RHBDL4. In light of our recent finding of the amyloid precursor protein (APP) family as efficient substrates of RHBDL4, we were enticed to further study the specific proteolytic mechanism of this enzyme by comparing cleavage patterns of wild type APP and APP TMS chimeras. Here, we demonstrate that the introduction of positively charged amino acid residues in the TMS redirects the RHBDL4-mediated cleavage of APP from its ectodomain closer towards the TMS, possibly inducing an ER-associated degradation (ERAD) of the substrate. In addition, we concluded that the cytoplasmic tail and proposed palmitoylation sites in the ectodomain of APP are not essential for the RHBDL4-mediated APP processing. In summary, our previously identified APP ectodomain cleavages by RHBDL4 are a subsidiary mechanism to the proposed RHBDL4-mediated ERAD of substrates likely through a single cleavage near or within the TMS.

Keywords: Alzheimer’s disease; cleavage mode; endoplasmic reticulum-associated degradation (ERAD); intramembrane protease; rhomboid protease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Protein Precursor / antagonists & inhibitors
  • Amyloid beta-Protein Precursor / metabolism*
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endoplasmic Reticulum-Associated Degradation / drug effects
  • HEK293 Cells
  • Humans
  • Leupeptins / pharmacology
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / metabolism*
  • Protease Inhibitors / pharmacology
  • Protein Processing, Post-Translational* / drug effects
  • Structure-Activity Relationship

Substances

  • Amyloid beta-Protein Precursor
  • Leupeptins
  • Membrane Proteins
  • Protease Inhibitors
  • RHBDL3 protein, human
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde